Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [615]

Prostate cancer updates: Advances in precision medicine and PARP inhibitors

Prof Karim Fizazi, Dr Joaquin Mateo, Dr Shahneen Sandhu and Prof Bertrand Tombal

Prostate cancer updates: Advances in precision medicine and PARP inhibitors ( Prof Karim Fizazi, Dr Joaquin Mateo, Dr Shahneen Sandhu and Prof Bertrand Tombal )

Breast cancer highlights from ESMO 2019

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer highlights from ESMO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Melanoma highlights from ESMO 2019

Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany

Melanoma highlights from ESMO 2019 ( Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany )

PARP inhibitor olaparib slows progression of advanced prostate cancer

Prof Maha Hussain - Northwestern University Feinberg School of Medicine...

PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )

Comment: PARP inhibitors for advanced prostate cancer

Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain

Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer

Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA )

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and...

Prof George Sledge - Stanford Health Care, Stanford, USA

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy ( Prof George Sledge - Stanford Health Care, Stanford, USA )

Providing quality patient care and service using the Oncology Care Model

Dr Vedner Guerrier - Memorial Healthcare System, Hollywood, FL, USA

Providing quality patient care and service using the Oncology Care Model ( Dr Vedner Guerrier - Memorial Healthcare System, Hollywood, FL, USA )

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA...

Prof Hope Rugo - University of California, San Francisco, USA

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

Ribociclib plus endocrine therapy improves survival in premenopausal patients...

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus...

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

More from ecancer